Is drug price policy evidence-based or evidence-deficient?

The federal government’s failed attempt to impose excessive price regulations on patented medicines reveals the information deficit in pharmaceutical policy.
Policymakers tend to see the prices of innovative medicines, but not the value, and this has resulted in a huge bureaucracy built to control the cost of patented drugs, writes Brett Skinner.
The Liberal Party’s 2015 federal election platform promised that its health policy decisions would be evidence based. But recent amendments to Canada’s patented medicines regulations show that the government's price control policies are based on faulty evidence and unproven assumptions, which ...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.


Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past week’s opinion writers and columnists on Saturdays and Sundays.


By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy

MORE Opinion

RELATED STORIES